Home > Press > SMI awarded DOE Phase II SBIR to develop p-type ZnO
SMI awarded DOE Phase II SBIR to develop p-type ZnO
Posted on February 02, 2006
Structured Materials Industries, Inc. (SMI) has been awarded a Phase II SBIR by the Department of Energy to develop p-type doping of ZnO. ZnO has shown great promise as an alternative to GaN as a blue light emitter.
Critical to demonstrating blue light emission in this material system is development of p-n junctions. While n-type material is easily achieved, p-type material has been very elusive with only a few scattered reports and with repeatability issues.
CVD is believed to be one of the best approaches to achieving p-type doping because of its ability to produce high quality films, greatly vary the chemistry and produce atomically abrupt layers when needed. For this program SMI has built a dedicated MOCVD system which it operates in-house.
About Structured Materials Industries:
Structured Materials Industries, Incorporated is focused on being the leader in Metal Organic Chemical Vapor Deposition (MOCVD) and related technologies. SMI offers for sale: systems, components, materials, and process development services. SMI has an in-house applications laboratory featuring multi-reactor deposition systems and analytic capabilities, has developed a range of strategic partnerships to develop and implement MOCVD technology and looks forward to continuing to grow and expand upon mutually advantageous relationships.
For more information, please click here.
General and Technical Information this release:
Dr. Gary S. Tompa
Structured Materials Industries, Inc.
Unit 102/103, 201 Circle Drive N.
Piscataway, New Jersey 08854
Copyright © Structured Materials Industries
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Malaysian Nanotechnology Company Nanopac Innovation Ltd. lists on the NSX January 19th, 2015
Aspen Aerogels, Inc. to Present at the Needham Growth Conference January 8th, 2015
Blend Therapeutics Secures $21 Million Financing and Unveils Novel Pentarin™ Platform for Cancer Therapeutics: Company’s Technology and Expertise in Cancer R&D Evolve to Create New Class of Miniaturized Biologic Drug Conjugates (mBDCs) Encapsulated in Nanoparticles January 8th, 2015
Nanometrics to Announce Fourth Quarter and Full Year Financial Results on February 2, 2015 January 7th, 2015
Iranian Researchers Planning to Produce Edible Insulin January 28th, 2015
Nanoparticles that deliver oligonucleotide drugs into cells described in Nucleic Acid Therapeutics January 28th, 2015
'Bulletproof' battery: Kevlar membrane for safer, thinner lithium rechargeables January 28th, 2015
Spider electro-combs its sticky nano-filaments January 28th, 2015
Joint international research project leads to a breakthrough in terahertz spectroscopy January 28th, 2015
JPK opens new expanded offices in Berlin to meet the growing demand for products worldwide January 28th, 2015
Pittcon News: Renishaw adds to the comprehensive imaging options available with its inVia confocal Raman microscope January 27th, 2015
Nanometrics to Present at the Stifel 2015 Technology, Internet and Media Conference January 27th, 2015